# The Role of VATS in Lung Cancer Surgery: Current Status and Prospects for Development

**Authors:** Dariusz Dziedzic, Tadeusz Orlowski

PMC · DOI: 10.1155/2015/938430 · 2015-07-29

## TL;DR

VATS has become a standard and effective minimally invasive surgical method for lung cancer, offering safety and comparable results to traditional techniques.

## Contribution

The paper highlights the evolution and current acceptance of VATS in lung cancer surgery despite initial debates.

## Key findings

- VATS is now widely accepted for early-stage lung cancer surgery.
- VATS outcomes are not inferior to traditional thoracotomy for cancer surgery.
- Improvements in equipment and technique have enhanced VATS application.

## Abstract

Since the introduction of anatomic lung resection by video-assisted thoracoscopic surgery (VATS) 20 years ago, VATS has experienced major advances in both equipment and technique, introducing a technical challenge in the surgical treatment of both benign and malignant lung disease. The demonstrated safety, decreased morbidity, and equivalent efficacy of this minimally invasive technique have led to the acceptance of VATS as a standard surgical modality for early-stage lung cancer and increasing application to more advanced disease. Formerly there was much debate about the feasibility of the technique in cancer surgery and proper lymph node handling. Although there is a lack of proper randomized studies, it is now generally accepted that the outcome of a VATS procedure is at least not inferior to a resection via a traditional thoracotomy.

## Linked entities

- **Diseases:** lung cancer (MONDO:0005138)

## Full-text entities

- **Genes:** CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}
- **Diseases:** metastases (MESH:D009362), lymphadenopathy (MESH:D008206), Pain (MESH:D010146), Lung collapse (MESH:D001261), air leak (MESH:D004618), Bronchopleural fistula (MESH:D005402), T3 (MESH:C537047), pneumothorax (MESH:D011030), pleural effusion (MESH:D010996), pulmonary nodules (MESH:D055613), infection complications (MESH:D002494), blood loss (MESH:D016063), pulmonary adhesions (MESH:D000267), pneumonia (MESH:D011014), nonsmall cell lung cancer (MESH:D002289), Cancer (MESH:D009369), thoracic injuries (MESH:D013898), bleeding (MESH:D006470), benign and malignant lung disease (MESH:D008171), Postoperative complications (MESH:D011183), tuberculosis (MESH:D014376), lymph node invasion (MESH:D008207), atrial fibrillation (MESH:D001281), myocardial infarction (MESH:D009203), T3 or T4 tumors (MESH:D005067), stage I and II (MESH:D062706), injury (MESH:D014947), lymph node (MESH:D000072717), pleural adhesions (MESH:D010995), Lung Cancer (MESH:D008175), postoperative pain (MESH:D010149)
- **Species:** Homo sapiens (human, species) [taxon 9606]

---
Source: https://tomesphere.com/paper/PMC4532864